FLT3 and cancer: The MTBP matches the cancer biomarkers aggregated across these knowledge bases with the variants observed in the tumor for (i) a specific nucleotide and/or protein amino acid change (e.g., BRCA1:c.5468-1G>A or KIT:p.D572A); (ii) a variant category (e.g., EGFR in-frame deletions in exon 19); or (iii) a functional entity (e.g., FLT3 oncogenic mutations, as guided by the MTBP functional interpretation) (Fig. 4a).